Targeted Protein Degradation
Merck KGaA Bolsters Protein Degradation Pipeline with $756M C4 Therapeutics Partnership
Merck KGaA, C4 Therapeutics, Targeted Protein Degradation, Collaboration, $756M Deal, Oncogenic Proteins, TORPEDO® Platform, Mid-Single to Low-Double Digit Tiered Royalties, Upfront Payment: $16 Million, Potential Milestone Payments: Up to $740 Million